Cargando…

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China

Objective: Long-acting injections (LAIs) of paliperidone palmitate have been shown to improve medication adherence and relieve psychotic symptoms. However, the specific cost-utility analysis of these LAIs in schizophrenia in China remains unclear. Methods: A multi-state Markov model was constructed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Rui, Lu, He, Li, Hengfen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435863/ https://www.ncbi.nlm.nih.gov/pubmed/37601057 http://dx.doi.org/10.3389/fphar.2023.1238028

Ejemplares similares

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
por: Patel, Charmi, et al.
Publicado: (2020)

Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs
por: Bramante, Stefano, et al.
Publicado: (2023)

Clinical Study of Paliperidone Palmitate Long-Acting Injection Combined With Electroacupuncture in the Treatment of Methamphetamine Addicts
por: Chen, Yu, et al.
Publicado: (2021)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
por: Abdall-Razak, Ali, et al.
Publicado: (2019)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea
por: Lee, Dasom, et al.
Publicado: (2020)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia
por: Zhang, Hongyan, et al.
Publicado: (2017)

The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia
por: Chiou, Chiun-Fang, et al.
Publicado: (2015)

T201. EFFECTS OF PALIPERIDONE PALMITATE ON HEALTHCARE UTILIZATION AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA: A CLAIM-BASED MIRROR-IMAGE STUDY IN SOUTH KOREA
por: Hun Jung, Myung, et al.
Publicado: (2020)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia
por: Elsisi, Gihan, et al.
Publicado: (2023)

A Case of Ileus in a Patient with Schizophrenia Under Paliperidone Palmitate Treatment
por: Can, Serdar Süleyman, et al.
Publicado: (2016)

Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
por: Bell Lynum, Karimah S., et al.
Publicado: (2018)

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

Different onset patterns of monthly paliperidone palmitate in hospitalised patient diagnosed with schizophrenia
por: Herrera-Sánchez, Javier, et al.
Publicado: (2021)

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
por: Emond, Bruno, et al.
Publicado: (2018)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

An accidental household outbreak of paliperidone palmitate poisoning via pancake consumption in Lianyungang, China
por: Zhang, Tinglu, et al.
Publicado: (2020)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O’Donnell, Amy, et al.
Publicado: (2021)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015)

Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
por: Hargarter, L, et al.
Publicado: (2016)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada, Ryohei, et al.
Publicado: (2018)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez, Alicia, et al.
Publicado: (2019)

The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study
por: Oh, So-Young, et al.
Publicado: (2019)

M217. EFFICACY OF PALIPERIDONE PALMITATE ON PSYCHIATRIC SYMPTOMS AND ATTITUDES TOWARD MEDICATION IN SCHIZOPHRENIA
Publicado: (2020)

Effects of Paliperidone Palmitate on Coagulation: An Experimental Study
por: Yılmaz, Enver Demirel, et al.
Publicado: (2014)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si, Tianmei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_98umi6hn1ee84ojur01t0rcetl